AEON AEON Biopharma, Inc. Loading... : Investor Sentiment and Bull/Bear Views
Loading chart...
Top Calls
No data yet
Price change since each call, adjusted for long/short direction. Results calculated:
Feed
17:54
Jan 15
Jan 15
351(k) biosimilar pivot could re-rate AEON at FDA meeting
Author argues AEON Biopharma is undervalued because its pivot to the 351(k) biosimilar pathway for ABP-450 could let it prove it is 'highly similar' to Botox and potentially cover all of Botox's approved uses under one license, avoiding separate Phase 3 trials. The near-term catalyst is the January 21 BPD Type 2a FDA meeting on the sufficiency of its analytical package; a positive green light could trigger a re-rating. The author also cites Daewoong's mid-December conversion of $15 million debt into equity as a balance-sheet cleanup and signal before the catalyst. Main stated risk: the FDA may still require heavy, expensive comparative clinical trials that could outpace AEON's cash runway.
HIGH
About AEON Investor Commentary
Across the available history and selected sources, Buzzberg tracks AEON (AEON Biopharma, Inc.) across 1 sources: 1 bullish vs 0 bearish calls from 1 authors. Historical directional balance: 100% = 100 × (bullish − bearish) / all deduplicated idea records, including other directions. This is neither a probability of a price rise nor the share of bullish authors. 1 total trade idea tracked. Latest voices: u/LowCommunication9778.